Erratum: Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome (Arteriosclerosis, Thrombosis, and Vascular Biology (2010) 30 (232-238) DOI: 10.1161/ATVBAHA.109.198226);Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 232-238

  Julve, Josep ^b   Escolà Gil, Joan Carles ^a,b   Rotllan, Noemi ^a,b   Fiévet, Catherine ^d,e   Vallez, Emmanuelle ^d,e   De La Torre, Carolina ^a,f   Ribas, Vicent ^a   Sloan, John H ^g,h   Blanco Vaca, Francisco ^a,b,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIV LILLE   (France)

^e INSERM   (France)

^f INSTITUT PASTEUR DE LILLE   (France)

^g UNIVERSITAT POMPEU FABRA   (Spain)

^h LINCO Diagnostic Services   (United States)

Author keywords

Chylomicron; Lipolysis; Proteomics; Transgenic mice; VLDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LIPOPROTEIN LIPASE; PROTEOME; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN EXPERIMENT; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; MASS SPECTROMETRY; MOUSE; NEPHELOMETRY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 75149135220     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATV.0b013e3181df5360     Document Type: Erratum

References (31)

1. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001;42:1727-1739.
2. Tailleux A, Duriez P, Fruchart JC, Clavey V. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 2002;164:1-13.
3. Kalopissis AD, Pastier D, Chambaz J. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol. 2003;14:165-172.
4. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol. 2004;15:247-253.
5. van't Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation. 2001;104:1223-1228.
6. Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, Straka RJ, Province M, Lai CQ, Parnell LD, Borecki I, Ordovas JM. The-256T > C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem. 2007;53:1144-1152.
7. Delgado-Lista J, Perez-Jimenez F, Tanaka T, Perez-Martinez P, Jimenez-Gomez Y, Marin C, Ruano J, Parnell L, Ordovas JM, Lopez-Miranda J. An apolipoprotein A-II polymorphism (-265T/C, rs5082) regulates postprandial response to a saturated fat overload in healthy men. J Nutr. 2007;137:2024-2028.
8. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res. 2003;92:1262-1267.
9. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116:2029-2035.
10. Dugue-Pujol S, Rousset X, Pastier D, Quang NT, Pautre V, Chambaz J, Chabert M, Kalopissis AD. Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism. J Lipid Res. 2006;47:2631-2639.
11. Castellani LW, Nguyen CN, Charugundla S, Weinstein MM, Doan CX, Blaner WS, Wongsiriroj N, Lusis AJ. Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. J Biol Chem. 2008;283:11633-11644.
12. Weng W, Breslow JL. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apoli-poprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA. 1996;93:14788-14794.
13. Boisfer E, Lambert G, Atger V, Tran NQ, Pastier D, Benetollo C, Trottier JF, Beaucamps I, Antonucci M, Laplaud M, Griglio S, Chambaz J, Kalopissis AD. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem. 1999;274:11564-11572.
14. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Marquez S, Gonzalez-Sastre F, Chan L. Functional lecithin:cho-lesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996;271:6720-6728.
15. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res. 1998;39: 313-321.
16. Escola-Gil JC, Julve J, Marzal-Casacuberta A, Ordonez-Llanos J, Gonzalez-Sastre F, Blanco-Vaca F. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res. 2001;42:241-248.
17. Julve J, Escola-Gil JC, Ribas V, Gonzalez-Sastre F, Ordonez-Llanos J, Sanchez-Quesada JL, Blanco-Vaca F. Mechanisms of HDL deficiency in mice overexpressing human apoA-II. J Lipid Res. 2002;43:1734-1742.
18. Pastier D, Dugue S, Boisfer E, Atger V, Tran NQ, van Tol A, Chapman MJ, Chambaz J, Laplaud PM, Kalopissis AD. Apolipoprotein A-II/A-I ratio is a key determinant in vivo of HDL concentration and formation of pre-beta HDL containing apolipoprotein A-II. Biochemistry. 2001;40: 12243-12253.
19. Ribas V, Palomer X, Roglans N, Rotllan N, Fievet C, Tailleux A, Julve J, Laguna JC, Blanco-Vaca F, Escola-Gil JC. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochim Biophys Acta. 2005;1737:130-137.
20. Broedl UC, Jin W, Fuki IV, Millar JS, Rader DJ. Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. J Lipid Res. 2006;47:2191-2197.
21. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304.
22. Heeren J, Beisiegel U. Intracellular metabolism of triglyceride-rich lipoproteins. Curr Opin Lipidol. 2001;12:255-260.
23. Taskinen MR, Glueck CJ, Kashyap ML, Srivastava LS, Hynd BA, Perisutti G, Robinson K, Kinnunen PJ, Kuusi T. Post-heparin plasma lipoprotein and hepatic lipases. Relationships to high density lipoprotein cholesterol and to apolipoprotein CII in familial hyperalphalipopro-teinemic and in normal subjects. Atherosclerosis. 1980;37:247-256.
24. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apo-lipoprotein A-IV. J Biol Chem. 1990;265:4266-4272.
25. Dallinga-Thie GM, Berk P II, Bootsma AH, Jansen H. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27:1358-1364.
26. Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J, Blanco-Vaca F. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its anti-oxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res. 2004;95:789-797.
27. Scanu AM, Lagocki P, Chung J. Effect of apolipoprotein A-II on the structure of high-density lipoproteins: relationship to the activity of leci-thin:cholesterol acyl transferase in vitro. Ann N Y Acad Sci. 1980;348: 160-173.
28. Schaefer EJ, Foster DM, Jenkins LL, Lindgren FT, Berman M, Levy RI, Brewer HB Jr. The composition and metabolism of high density lipoprotein subfractions. Lipids. 1979;14:511-522.
29. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 1987;80:341-347.
30. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res. 1982;23:747-753.
31. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29:870-876.